Moreover, the 36-month beta value for MRNS is 1.27. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MRNS is 42.43M and currently, short sellers hold a 13.35% of that float. On November 13, 2024, MRNS’s average trading volume was 2.37M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MRNS) stock’s latest price update
The stock price of Marinus Pharmaceuticals Inc (NASDAQ: MRNS) has plunged by -7.07 when compared to previous closing price of 0.34, but the company has seen a -4.30% decline in its stock price over the last five trading sessions. zacks.com reported 2024-11-12 that Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.61 per share a year ago.
MRNS’s Market Performance
Marinus Pharmaceuticals Inc (MRNS) has seen a -4.30% fall in stock performance for the week, with a -81.58% decline in the past month and a -73.73% plunge in the past quarter. The volatility ratio for the week is 10.79%, and the volatility levels for the past 30 days are at 17.64% for MRNS. The simple moving average for the last 20 days is -53.75% for MRNS stock, with a simple moving average of -90.45% for the last 200 days.
Analysts’ Opinion of MRNS
Many brokerage firms have already submitted their reports for MRNS stocks, with Oppenheimer repeating the rating for MRNS by listing it as a “Outperform.” The predicted price for MRNS in the upcoming period, according to Oppenheimer is $6 based on the research report published on September 23, 2024 of the current year 2024.
Robert W. Baird gave a rating of “Neutral” to MRNS, setting the target price at $2 in the report published on April 16th of the current year.
MRNS Trading at -74.60% from the 50-Day Moving Average
After a stumble in the market that brought MRNS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.15% of loss for the given period.
Volatility was left at 17.64%, however, over the last 30 days, the volatility rate increased by 10.79%, as shares sank -82.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -77.46% lower at present.
During the last 5 trading sessions, MRNS fell by -4.45%, which changed the moving average for the period of 200-days by -96.80% in comparison to the 20-day moving average, which settled at $0.6930. In addition, Marinus Pharmaceuticals Inc saw -97.05% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRNS starting from Pfanstiel Steven, who sale 4,657 shares at the price of $1.13 back on Aug 05 ’24. After this action, Pfanstiel Steven now owns 79,773 shares of Marinus Pharmaceuticals Inc, valued at $5,262 using the latest closing price.
Shafer Christina, the CHIEF COMMERCIAL OFFICER of Marinus Pharmaceuticals Inc, sale 3,820 shares at $1.14 during a trade that took place back on Aug 05 ’24, which means that Shafer Christina is holding 67,406 shares at $4,355 based on the most recent closing price.
Stock Fundamentals for MRNS
Current profitability levels for the company are sitting at:
- -4.47 for the present operating margin
- 0.89 for the gross margin
The net margin for Marinus Pharmaceuticals Inc stands at -4.93. The total capital return value is set at -2.64. Equity return is now at value -2986.55, with -103.54 for asset returns.
Based on Marinus Pharmaceuticals Inc (MRNS), the company’s capital structure generated 2.06 points at debt to capital in total, while cash flow to debt ratio is standing at -1.31. The debt to equity ratio resting at -1.94. The interest coverage ratio of the stock is -14.98.
Currently, EBITDA for the company is -125.5 million with net debt to EBITDA at -0.23. When we switch over and look at the enterprise to sales, we see a ratio of 1.62. The receivables turnover for the company is 8.81for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.28.
Conclusion
To wrap up, the performance of Marinus Pharmaceuticals Inc (MRNS) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
